Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DMAC vs ENTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DMAC Captures Overall Composite Edge (46.3 HOLD vs 46.2 HOLD), While ENTA Leads 3–2 on Growth & Valuation Pillars
DMAC Overall Winner
6-Pillar Tally: DMAC 2 – 3 ENTA (1 Tie)
Matrix Metrics: DMAC 5 – 4 ENTA
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (46.3/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 5–4 (led by Growth & Scale, Profitability & Quality), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.39 (N/M Forward P/E, 0.0% operating margin) versus ENTA at $10.79 (44.0x Forward P/E, -90.0% operating margin).
- Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.72β · 97% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DMAC vs ENTA
DMAC
Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
$8.39
-4.55% 1D
Market Cap
$503.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.72β · 97% Vol
Unified Composite Score
46.3
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
ENTA
Enanta Pharmaceuticals, Inc
$10.79
-1.82% 1D
Market Cap
$326.2M
TTM Revenue
$65M
Forward P/E
44.0x
Beta / 30D Vol
0.89β · 58% Vol
Unified Composite Score
46.2
HOLD
Tech 53.0
Fund 54.0
Flow 67.0
Mom 50.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 3 ENTA)
1. Valuation Multiples
ENTA
Forward P/E
N/M
44.0x
Trailing P/E
N/M
44.0x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
5.3x
2. Growth & Scale
DMAC
Revenue Growth (YoY)
+0.0%
-21.6%
Earnings Growth (YoY)
+0.0%
-66.2%
TTM Revenue (USD)
N/A
$65M
Market Cap
$503.1M
$326.2M
3. Profitability & Quality
DMAC
Gross Margin
N/A
100.0%
Operating Margin
0.0%
-90.0%
Net Profit Margin
0.0%
-96.9%
Return on Equity (ROE)
-114.6%
-70.1%
4. Balance Sheet & Cash Flow
ENTA
Cash Generation (TTM)
-$32M
-$37M
Cash Flow Margin
N/A
-56.6%
Net Cash / Leverage
$4.9M Net Cash
$22M Net Debt (0.55x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
ENTA
Options Structure Phase
SURGE
BREAKDOWN
Current IV / %ile
106.3% (14th %ile)
78.7% (11th %ile)
Put/Call OI Skew
N/A
0.31x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DMAC (5) vs ENTA (4)| Institutional Metric | DMAC | ENTA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $503.1M | $326.2M | DMAC | |
| Trailing P/E Ratio | N/M | 44.0x | ENTA | |
| Forward P/E Ratio | N/M | 44.0x | ENTA | |
| Revenue Growth (YoY) | +0.0% | -21.6% | DMAC | |
| Operating Margin (TTM) | 0.0% | -90.0% | DMAC | |
| Net Profit Margin | 0.0% | -96.9% | DMAC | |
| Return on Equity (ROE) | -114.6% | -70.1% | ENTA | |
| 52-Week Range Position | 55% ($5–$11) | 10% ($10–$17) | DMAC | |
| Beta / 30D Volatility | 1.72β · 97% Vol | 0.89β · 58% Vol | ENTA | |
| Unified Institutional Score | 46.3 / 100 (HOLD) | 46.2 / 100 (HOLD) | Tie | |
| Trailing 12M Revenue (USD) | N/A | $65M | Scale | |
| Gross Profit Margin (TTM) | N/A | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 5.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M ($4.9M Net Cash) | -$37M ($22M Net Debt (0.55x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DMAC +13.62 pp
3M Horizon
DMAC +45.8 pp
6M Horizon
DMAC +67.49 pp
1Y Horizon
DMAC +62.74 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | ENTA Revenue | DMAC Op. Margin | ENTA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $210M | -1352.2% | 42.7% | ENTA |
| FY2019 | N/A | $210M | N/A | 17.9% | ENTA |
| FY2020 | N/A | $120M | N/A | -34.0% | ENTA |
| FY2021 | N/A | $100M | N/A | -112.9% | ENTA |
| FY2022 | N/A | $90M | N/A | -143.7% | ENTA |
| FY2023 | N/A | $80M | N/A | -173.2% | ENTA |
| FY2024 | N/A | $70M | N/A | -179.9% | ENTA |
| FY2025 | N/A | $70M | N/A | -130.7% | ENTA |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DMAC
SURGE
Current IV
106.3%
IV Percentile
14th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ENTA
BREAKDOWN
Current IV
78.7%
IV Percentile
11th %ile
Put/Call OI Skew
0.31x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DMAC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ENTA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DMAC vs ENTA Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (46.3/100 HOLD vs. 46.2/100 HOLD) after splitting the core matrix 5–4 (led by Growth & Scale, Profitability & Quality), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.39 (N/M Forward P/E, 0.0% operating margin) versus ENTA at $10.79 (44.0x Forward P/E, -90.0% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. ENTA 46.2/100 HOLD) and 1.72β · 97% Vol risk profile, whereas ENTA leads top-line expansion (-21.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DMAC leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while ENTA shifted -66.7%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.
ENTA screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus ENTA (-70.1% ROE) capital efficiency.
In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.72β · 97% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ENTA vs DMAC · Reverse Pair
DMAC vs TRVI
· Sector Peer
DMAC vs VRCA
· Sector Peer
DMAC vs FENC
· Sector Peer
ENTA vs XNCR
· Sector Peer
ENTA vs PTCT
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem